Research graph
References from Effects of neurokinin receptor antagonists on sleep disturbance in menopausal women: a systematic review and meta-analysis of randomized controlled trials. Local targets link to admitted publications; unresolved targets remain external evidence.
The 2023 nonhormone therapy position statement of The North American Menopause Society
10.1097/gme.0000000000002200 · 2023 · External reference
Evaluation and management of sleep disturbance during the menopause transition
10.1055/s-0030-1262900 · 2010 · External reference
Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey
10.1097/gme.0000000000002237 · 2023 · External reference
Sleep disturbance associated with the menopause
10.1097/gme.0000000000002386 · 2024 · External reference
The 2022 hormone therapy position statement of The North American Menopause Society
10.1097/gme.0000000000002028 · 2022 · External reference
Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
10.1016/j.xcrm.2023.101076 · 2023 · External reference
Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature
10.1073/pnas.1211517109 · 2012 · External reference
Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes
10.1016/j.yfrne.2013.07.003 · 2013 · External reference
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
10.1016/s0140-6736(23)00085-5 · 2023 · External reference
Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial
10.1001/jamainternmed.2025.4421 · 2025 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
10.1136/bmj.39489.470347.ad · 2008 · External reference
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
10.1186/1471-2288-14-135 · 2014 · External reference
Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
10.1177/0962280216669183 · 2018 · External reference
Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials
10.1001/jama.2024.14618 · 2024 · External reference
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)
10.1097/gme.0000000000002138 · 2023 · External reference
Effect of fezolinetant on patient-reported quality-of-life outcomes: data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy
10.1016/j.maturitas.2024.108159 · 2025 · External reference
Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause
10.1016/j.maturitas.2024.107999 · 2024 · External reference
Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial
10.1210/jc.2019-00677 · 2019 · External reference
Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: a matching-adjusted indirect comparison
10.1016/j.maturitas.2025.108782 · 2026 · External reference
Fezolinetant’s efficacy and safety in treatment of vasomotor symptoms in postmenopausal women: a meta-analysis and GRADE evaluation of randomized controlled trials
10.1186/s40001-025-02279-y · 2025 · External reference
Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause
10.1186/s41687-025-00875-4 · 2025 · External reference
Sleep and sleep disorders in the menopausal transition
10.1016/j.jsmc.2018.04.011 · 2018 · External reference
Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance
10.1097/01.gme.0000227398.53192.bc · 2006 · External reference
Substance P and the neurokinin-1 receptor regulate electroencephalogram non-rapid eye movement sleep slow-wave activity locally
10.1016/j.neuroscience.2014.08.062 · 2015 · External reference
Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia
10.5665/sleep.3208 · 2013 · External reference
Menopausal symptoms and their management
10.1016/j.ecl.2015.05.001 · 2015 · External reference
Advances in pharmacotherapy for menopausal vasomotor symptoms
10.1007/s40265-025-02231-8 · 2025 · External reference
